Ph.D. Michael Exton - 28 Feb 2026 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)

Role: Chief Executive Officer, Director
Signature: /s/ Michael Exton, Ph.D.
Issuer symbol: LXRX
Transactions as of: 28 Feb 2026
Net transactions value: -$301,102
Form type: 4
Filing time: 03 Mar 2026, 07:15:34 UTC
Previous filing: 17 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Exton Michael	Chief Executive Officer, Director	2445 TECHNOLOGY FOREST BLVD, 11TH FLOOR, THE WOODLANDS	/s/ Michael Exton, Ph.D.	03 Mar 2026	0002029249

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LXRX	Common Stock	Options Exercise		+503,263			503,263	28 Feb 2026	Direct	F1
transaction	LXRX	Common Stock	Tax liability	$301,102	-204,831	-41%	$1.47	298,432	28 Feb 2026	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LXRX	Restricted Stock Units	Options Exercise		-503,263	-33%		1,006,527	28 Feb 2026	Common Stock	503,263		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of common stock.
F2	Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.
F3	Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.